Fracture

Haque S et al. Curr Treat Options in Rheum 2018; Advance online publication. doi: 10.1007/s40674-018-0099-x

Quesada-Gomez JM, Bouillon R. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4520-y

Wong EKC, Papaioannou A. Curr Treat Options in Rheum 2018; Advance online publication. doi: 10.1007/s40674-018-0098-y

Benetou V et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4517-6

Walsh JA et al. Clin Rheumatol 2018; Advance online publication. doi: 10.1007/s10067-018-4086-2.

The authors report the case of a 24-year-old woman diagnosed with glucocorticoid-induced osteoporosis in which initial treatment with teriparatide followed by treatment of kyphosis with correction fusion achieved a favorable outcome.

Uei H et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4425-9

Anagnostis P et al. Endocrine 2018; Advance online publication. doi: 10.1007/s12020-018-1548-x

Results of the phase III ARCH trial suggest that women with osteoporosis who are treated with romosozumab are less likely to experience fractures, but may have an increased risk for cardiovascular events, compared with those given alendronate.

Heinlen & Humphrey review the clinical evidence for abnormal skeletal health in patients with rheumatoid arthritis and the effects of disease modifying anti-rheumatic drugs on bone health.

Heinlen L, Humphrey MB. Osteoporos Int 2017. doi:10.1007/s00198-017-4170-5

This case report describes a 38-year-old woman, who presented with bilateral femoral stress fractures and osteoporosis after years of excessive levothyroxine treatment. How would you respond when presented with such a patient?

Laine CM, K. Landin-Wilhelmsen K. Osteoporos Int 2017; 28: 2247–2250. doi:10.1007/s00198-017-3981-8

Patients with spondyloarthritis are at increased risk of developing certain comorbidities that may have adverse impacts on health outcomes and management of and may be associated with increased health care costs. This is reviewed in this article.

Danve A and Raychaudhuri SP. Curr Treat Options in Rheum 2017;3:63. doi:10.1007/s40674-017-0061-3

Alonso N, Calero-Paniagua I, del Pino-Montes J. Clinic Rev Bone Miner Metab 2017; 15: 37. doi: 10.1007/s12018-016-9226-0

In this chapter, the authors provide an overview of the latest epidemiological data on osteoporosis in the US including rates of osteoporosis and fragility fractures.

Bone Disorders. Springer International Publishing Switzerland, 2017. doi:10.1007/978-3-319-29182-6_16

This chapter describes the non-pharmacological approaches to the prevention of falls and fall-related injuries in older people, and emphasises effective strategies in a range of population groups.

Lord SR, Close JCT, Sherrington C. In: Osteoporosis in Older Persons. Edited by Duque G, Kile DP. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-25976-5_12

An expert review of epidemiologic data on the rates of hip and other common fractures among older individuals and future projections on hip and other common fractures.

Bischoff-Ferrari HA. In: Osteoporosis in Older Persons. Edited by Duque G, Kile DP. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-25976-5_9

In this chapter, the authors review the importance of genetic risk factors for the development of generalized osteoporosis and in relation to fracture rates in the elderly.

Karasik D, Kiel DP. In: Osteoporosis in Older Persons. Edited by Duque G, Kile DP. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-25976-5_8

Lindsay et al. conclude that osteoporosis patients at high risk for fracture being treated with teriparatide should follow the full 24-month treatment course in order to achieve the best clinical outcomes.

Lindsay R et al. Osteoporos Int 2016;27:2395–2410. doi:10.1007/s00198-016-3534-6

This chapter explores the epidemiology of osteoporosis and fragility fracture, cell biology and biomechanics, and the latest research on global trends in age- and sex-specific fracture rates.

Moon RJ, Cooper C, Harvey NC. In: The Duration and Safety of Osteoporosis Treatment. Edited by Silverman S, Abrahamsen B. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-23639-1_1